Zai Lab has received approval from China’s National Medical Products Administration (NMPA) for the supplemental new drug ...

If you are wondering whether Zai Lab's current share price reflects its real value, this article walks through what the ...

Smiley also details how Zai Lab blends China’s development speed capabilities with global clinical and regulatory standards, ...

Zai Lab Limited (NASDAQ:ZLAB) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 6, ...

Zai Lab offers a weaker value proposition for investors looking to bet on Chinese biotech due to its pure license in approach, limiting its potential to tap into global market. Its key products have ...

– Total revenues grew 22% y-o-y to $106.5 million for the first quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million – Operating loss improved significantly, ...

Zai Lab is blazing a new path to realizing our vision of becoming a leading global biopharmaceutical company. Our company is focused on discovering, developing and delivering treatments that address ...

Zai Lab has stopped development of a treatment for atopic dermatitis after it failed to beat placebo in a phase 2a trial. The Shanghai-based biotech licensed the candidate from GlaxoSmithKline in 2016 ...

A federal judge sentenced Eddy Zai to seven years and three months in prison for defrauding a credit union out of what prosecutors said amounted to $10 million. (Photo by Plain Dealer file) Updated ...